arrow
D

Didier Surdez

University of Zurich
H指数:35
被引数:8,014

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

HIF1α gates tendon response to overload and drives tendinopathy independently of vascular recruitment
2026-01-070
PRE
The hegemonic EWSR1::ETS oncoprotein overrules core regulatory circuitry principles in Ewing sarcoma

优势性的EWSR1::ETS癌蛋白在尤文氏肉瘤中推翻了核心调控回路原理。

2025-12-250
OAAI
Interest of a sequential multimodal approach for the treatment of newly diagnosed patients with multimetastatic Ewing sarcoma: results of the French prospective CombinaiR3 phase II trial

对于新诊断的多发性转移性尤因肉瘤患者,采用序贯多模式治疗方法的临床价值:法国前瞻性CombinaiR3 II期试验结果

2025-11-170
PRE
Patient-derived tumoroids from CIC::DUX4 rearranged sarcoma identify MCL1 as a therapeutic target

CIC::DUX4易位的肉瘤来源类器官鉴定MCL1为治疗靶点

2025-08-210
OAAI
Clonal decomposition and DNA replication states defined by scaled single-cell DNA and RNA sequencing suggest clone-specific therapeutic vulnerabilities in neuroblastoma
2024-09-050
PRE
Targeting boundary cap cells leads to mouse Smarcb1-deficient peripheral nerve tumors recapitulating human peripheral rhabdoid tumors
2024-09-050
PRE
ITCC-P4, a preclinical proof-of-concept drug testing platform as a tool for pharmacological screening in pediatric tumor models

ITCC-P4,一个临床前概念验证药物测试平台,作为儿科肿瘤模型药理筛选的工具

2024-03-220
PRE
Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer

AXL在融合阳性小儿横纹肌肉瘤中的作用评估将小分子抑制剂Bemcentinib (BGB324) 确定为有效的化学增敏剂

2024-03-121
OAAI
PAX3-FOXO1 uses its activation domain to recruit CBP/P300 and shape RNA Pol2 cluster distribution
2023-12-155
OAAI
Imaging and multi-omics datasets converge to define different neural progenitor origins for ATRT-SHH subgroups
2023-10-204
OAAI
A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors
2023-09-188
OAAI
SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistance
2023-05-2613
OAAI
Reversible transitions between noradrenergic and mesenchymal tumor identities define cell plasticity in neuroblastoma
2023-05-0425
OAAI
The ITCC-P4 sustainable platform of fully characterized PDXs supports the preclinical proof-of-concept drug testing of high-risk pediatric tumor models

完全表征的PDXs的ITCC-P4可持续平台支持高风险儿科肿瘤模型的临床前概念验证药物测试

2023-04-041
PRE